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The liver carries out a range of functions essential for bodily homeostasis. The impairment of liver functions has serious
implications and is responsible for high rates of patient morbidity and mortality. Presently, liver transplantation remains the
only eﬀective treatment, but donor availability is a major limitation. Therefore, artificial and bioartificial liver devices have been
developed to bridge patients to liver transplantation. Existing support devices improve hepatic encephalopathy to a certain extent;
however their usage is associated with side eﬀects. Themajor hindrance in the development of bioartificial liver devices and cellular
therapies is the limited availability of human hepatocytes. Moreover, primary hepatocytes are diﬃcult to maintain and lose hepatic
identity and function over time even with sophisticated tissue culture media. To overcome this limitation, renewable cell sources
are being explored. Human embryonic stem cells are one such cellular resource and have been shown to generate a reliable and
reproducible supply of human hepatic endoderm. Therefore, the use of human embryonic stem cell-derived hepatic endoderm in
combination with tissue engineering has the potential to pave the way for the development of novel bioartificial liver devices and
predictive drug toxicity assays.
1. Introduction
The liver is the largest gland in the body and carries out
a multitude of endocrine and exocrine functions [1]. The
liver also possesses a remarkable regenerative capability;
however, upon repeated injury it becomes progressively
fibrosed and loses function. Existing treatments for patients
with end stage liver diseases or acute liver failure are
reliant upon liver cell or organ transplantation [2]. The
mortality rate is as high as 80% in fulminant hepatic
failure (FHF) in the absence of transplantation [3].
Approximately 6,000 liver transplant operations are per-
formed in the United States (http://www.liverfoundation
.org/education/info/transplant/) and about 600–700 in the
UK every year (http://www.britishlivertrust.org.uk/home/
the-liver/liver-transplantation/a-history-of-liver-transplan-
tation-and-current-statistics.aspx), but these numbers are
limited by the availability of donor organs. In order
to overcome this, the practice of living donor liver
transplantation was introduced in 1989 [4]. A living
donor is usually a blood relative who undergoes surgery in
which a section of the liver is removed for transplantation
into the recipient. Liver regeneration then occurs in both
the donor and recipient over a period of 8–12 weeks. While
promising, this is a complex, high risk procedure from which
20% of donors develop complications, and the associated
ethical issues complicate its routine clinical deployment
[5]. This has necessitated the exploration of alternative
approaches to support human liver function during liver
failure. One such approach receiving recent attention is the
development of extracorporeal devices utilising hepatocytes
to provide support during liver failure [6].
In addition to cell therapeutic approaches, another
important aspect of human liver cell biology is the testing
and safe development of new drugs, as the liver plays a central
role in the metabolism of the majority of drugs [7]. Several
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in vitro human liver models have been developed including
supersomes [8], microsomes, cytosol, S9 fraction, cell lines,
liver slices and perfused lines. Although useful, these models
suﬀer functional drawbacks, which aﬀect drug attrition and
therefore development costs [8, 9]. A standardized in vitro
tissue model for screening new drug compounds for toxicity
and eﬃcacy would be more predictive of the human liver.
Recent advances in stem cell research and tissue engineer-
ing have opened up several new avenues for the development
of novel cell-based therapies and in vitro techniques for
hepatology research. This paper gives an overview of the
stem cell and tissue engineering approaches that have been
developed or adapted by diﬀerent research groups, with
special emphasis on the derivation of hepatic endoderm
(HE) from human embryonic stem cells (hESCs), and its
clinical application in regenerative medicine.
2. Tissue Engineering and
Regenerative Medicine
Regenerative medicine and tissue engineering are branches
of medicine which focus on the creation of living, functional
tissues to repair or replace damaged tissues or organs and
restore their function [10, 11]. Together, they promise enor-
mous therapeutic opportunity and may play an important
role in reducing the need for whole organ transplantation
and greatly accelerate the development of new drugs and
medicines [12].
3. Liver Diseases
FHF is the most serious of all liver diseases and is usually
defined as the severe impairment of hepatic function in the
absence of pre-existing liver disease. It can occur within
10 days of liver dysfunction (hyper-acute), within 10–31
days (acute) or after more than 31 days (subacute). The
pathophysiology of this condition consists of the loss of hep-
atocellular function causing severe metabolic derangements,
impairment of plasma detoxification, hyperammonemia
(elevated blood ammonia levels), neurological complica-
tions, and systemic organ failure [13, 14]. Acute-on-chronic
liver disease occurs in patients with well compensated
chronic liver disease in whom acute deterioration of liver
function occurs due to events such as sepsis, gastrointestinal
bleeding, ischemia or additional superimposed liver injury
due to alcohol, hepatotoxic drugs, or viral infections. It
is characterised by systemic circulatory disturbances, hepa-
torenal failure, and hepatic encephalopathy. Chronic hepatic
decompensation occurs in patients with end stage cirrhosis
and underlying liver disease [15–17].
The onset of liver failure is potentially reversible, and
considerable work has been carried out to develop eﬀective
support devices capable of emulating human liver function
to allow patient recovery following acute deterioration [18].
Artificial liver and bioartificial liver devices have been
specifically developed to bridge patients until either a suitable
organ becomes available for transplantation, or recovery
occurs in the patient.
4. Artificial Liver Devices (ALDs)
The key factors identified in the pathophysiology of hepatic
encephalopathy in liver disease are hyperammonemia caused
by urea cycle enzyme deficiency, and changes in levels
of GABA, benzodiazepines, 5-HT, aromatic amino acids,
mercaptens, phenols, and fatty acids [19, 20]. Artificial
liver devices are designed to filter the accumulation of
these toxic substances using the principles of hemofiltration,
hemoperfusion, and hemodiabsorption [3]. Although ALDs
have produced clinical improvements in some patients,
significant increases in survival rates have not been obtained
[21]. Moreover, there are side eﬀects associated with such
filtration techniques, for example, incompatibility between
blood and extracorporeal circuit causing complement initi-
ation, platelet activation, and leucopoenia (decreased white
blood cell count) leading to systemic inflammatory response
and hemorrhaging. Another drawback of filtration is that
it removes some of the hormones and growth factors
involved in liver regeneration [3]. The plasma exchange
systemwas developed to overcome these drawbacks, allowing
the removal of hepatic toxins while replacing the beneficial
factors. However, this process is expensive and associated
with coagulation imbalance and citrate load, limiting its
clinical applicability [3].
One of the most commonly used ALDs is the molecular
adsorbents recirculating system (MARS). The MARS uses
albumin enriched dialysate, a charcoal filter, and an ion
exchange resin to filter out albumin-bound toxic metabo-
lites which may precipitate encephalopathy and multiorgan
failure. The MARS circuit is impermeable to albumin but
allows the diﬀusion of toxic molecules bound to albumin
[22]. TheMARS has been reported to produce improvements
in physiological and neurological states but again does not
significantly improve survival rates [21, 23]. Like other
ALDs, it does not discriminate which molecules are filtered
and therefore can remove key cytokines involved in liver
regeneration such as IL-6 and TNF [3].
The Prometheus system is another ALD which has
undergone clinical trial for the treatment of patients with
acute-on-chronic liver failure. This system uses fractional
plasma separation and an adsorption method with high flux
hemodialysis using an albumin semipermeable membrane. It
has been shown to be more eﬀective than the MARS system
at clearing albumin bound toxins, but oﬀers no improvement
in hemodynamics [24, 25]. The complications associated
with these techniques demonstrate the shortcomings of
nonbiologic liver support devices. The detoxification of
patients’ blood using entirely artificial systems is far from an
ideal support system for the failing organ. It is now being
realized that a device with a biological component capable
of performing all the metabolic and detoxifying functions of
the liver could be a much more eﬀective strategy [26, 27].
5. Bioartificial Liver Devices
The limitations of ALDs discussed above, along with the
scarcity of donor livers, have led to the development of exter-
nal liver support devices incorporating primary hepatocytes
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known as bioartificial livers (BALs). Ideally, a BAL should
be able to simulate the function of the entire liver, though
existing designs have yet to meet this requirement [28]. The
use of living tissue in external liver support devices dates
back to the 1950s, and a pioneering trial in which patients
with cirrhosis were treated using cross-hemodialysis of the
patients’ blood with that of four living dogs [29]. One patient
of four showed a reduction in serum ammonia levels and
temporarily recovered from a hepatic coma. However, the
technique was complicated, nonscalable and had little long
term clinical impact. The true potential of extracorporeal
liver perfusion systems was not realised until the 1990s,
when human cadaveric livers that were unsuitable to be
transplanted were used to successfully bridge patients with
acute hepatic failure to transplantation [30].
Although early BAL studies showed great promise, there
are a number of problems associated with the use of primary
hepatocytes. Maintaining the long-term metabolic functions
of BALs is diﬃcult as mature hepatocytes scarcely prolif-
erate and rapidly lose their hepatic function ex vivo [31].
Bioartificial liver support using an Academic Medical Centre
(AMC) BAL bioreactor has demonstrated eﬃcacy in phase
I clinical trials, in which patients exhibited improvements
in neurological status and hemodynamics [32]. In one
case a patient on the transplant list fully recovered and
did not require solid organ transplantation [33]. Although
promising, these trials were conducted using a BAL charged
with porcine hepatocytes, and concerns have been raised over
the safety of using animal cells in clinical therapies due to
the possibility of disease transmission. In support of this,
a recent paper by Fru¨hauf et al. [34] demonstrated that
porcine hepatocyte-fuelled BALs were able to infect primary
human hepatocytes with the porcine retrovirus. The risks
associated with using liver support devices incorporating
animal tissue have limited their clinical application, and the
use of porcine hepatocytes for BAL treatment is prohibited in
several European countries [35]. Other bioartificial devices
such as Hepta Assist, Modular Extracorporeal Liver Support,
Bioartificial Support System, and Radial Flow Bioreactor
have also been used in Phase I clinical trials (reviewed in
[26]). The extracorporeal liver assist device (ELAD) charged
with the human cell line C3A has been shown to be of
advantage in patients with FHF in terms of bridging to
transplantation, although human cell lines generally display
poor liver function [36]. A fully functioning humanised
alternative to porcine hepatocytes could lead to a stable
and reliable solution to the problem of managing and
treating human liver disease. Eﬀorts to achieve this feat
have been focussed on the emerging fields of stem cell
research and tissue engineering. There are three key criteria
to consider in the development of stem cell derived liver
technology: expandable cellular resource, eﬃcient directed
diﬀerentiation, and high fidelity function.
6. Hepatocellular Resources
Hepatocytes constitute about two thirds of the total cell
population in the liver parenchyma and perform a variety
of endocrine and exocrine functions. The remaining popu-
lation of nonparenchymal cells is diverse and includes liver
sinusoidal endothelial cells, kupﬀer cells, biliary cells, stellate
cells, and intrahepatic lymphocytes [37]. Primary human
hepatocytes (PHHs) are used to model various aspects of
liver biology in vitro. The pharmaceutical industry takes
particular interest in the expression and function of drug
metabolising enzymes such as cytochrome P450 (CYP), drug
metabolism, drug interactions, cytotoxicity, and genotoxicity
in these models [38]. A major limitation of such in vitro
studies is the shortage and variability of isolated PHHs. High
quality donor livers are used for transplantation, therefore
PHHs are generally sourced from smaller fragments of liver
tissue resected for medical purposes such as primary liver
metastasis, adenoma, angioma, fatty liver, and hydatid cysts
[39, 40].
The liver is a remarkable organ as even after 70%
resection it is capable of regeneration by compensatory
hyperplasia within a few weeks. Hepatocyte proliferation and
the growth of cellular mass are induced by cytokines from
kupﬀer cells and stellate cells, and this is then followed by
the proliferation of endothelial cells and cholangiocytes [41].
Despite the liver’s resilience and capacity for regeneration
it has proven extremely diﬃcult to maintain or expand
hepatocytes in cell culture [42]. Even with sophisticated
media, human hepatocytes dediﬀerentiate extensively within
a few hours of plating [8, 9], losing hepatic specific gene
expression and function [42]. At present, most studies are
conducted with human cell lines and rodent hepatocytes.
Although a readily available replacement for PHHs, these
models suﬀer from poor function and species specific
variation, complicating data extrapolation to humans. An
example of this occurring is the case of Troglitazone,
which is a member of the thiazolidinedione class of oral
hypoglycaemic agents. It was approved for marketing by the
Food and Drug Administration (FDA) in March 1997, but
was withdrawn from the market in March 2000 after causing
at least 90 cases of liver failure, 70 of which resulted in
death or transplantation [43]. Current attention is focussed
on finding a reliable source of human hepatocytes. The
generation of hepatic endoderm from pluripotent stem cells
is now being identified as one such resource to meet this
demand [27]. Human embryonic stem cells are derived
from the inner cell mass of preimplantation embryos and
possess the ability to self-renew and diﬀerentiate to all cell
types [44, 45]. These attributes in theory give them the
potential to provide an unlimited supply of replacement
cells for regenerative medicine [46]. Their adult and fetal
stem cell counterparts have also been suggested as potential
cell sources, but these have limited capacity to multiply as
compared to hESCs. Moreover, they are present in minute
quantities, are diﬃcult to isolate and purify.
7. Directed Differentiation of hESCs to
Hepatic Endoderm
Using developmental signalling physiology, it is possible
to drive hESC diﬀerentiation to functional HE [47–60].
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Figure 1: Schematic diagram of the derivation of hepatic endoderm
from human embryonic stem cells.
This can be achieved either by spontaneous diﬀerentiation
through the formation of embryoid bodies (EBs), or by
direct diﬀerentiation (Figure 1). Spontaneous diﬀerentiation
of hESCs results in the formation of EBs consisting of a
mixed cell population of all three germ layers [48]. These
EBs have been shown to diﬀerentiate spontaneously into HE
[47, 49, 50], but this occurs with limited eﬃciency. Recently,
specific growth factors have been identified to direct hepatic
diﬀerentiation following EB formation. However, diﬀerenti-
ated cell populations still require purification following this
process [51]. A number of studies have shown that faster,
more eﬃcient production of HE can be achieved through
direct diﬀerentiation without the formation of EBs [52–57].
In 2007 we described the diﬀerentiation of HE from
hESCs. Although the hESC derived HE was shown to exhibit
hepatocyte morphology, gene expression, and function, the
yield was only 10%. Following on from this, we developed
a more eﬃcient diﬀerentiation protocol by priming hESC
diﬀerentiation to HE [53]. Further work in our laboratory
identified activin A and Wnt3a signalling as key factors
in the development of functional HE, and demonstrated
for the first time highly eﬃcient and scalable derivation of
functional HE derived from hESCs [54, 55].
In the future hESCs could potentially provide an inex-
haustible source of hepatocytes, but their utility in both
cell-based assays and the clinic depends on their functional
repertoire [58–60]. Stem cells and somatic cells generally
have limited function without the specialized tissuemicroen-
vironment known as the “niche.” Key niche components
and interactions in vivo include growth factors, cell-cell
contacts, and cell-matrix adhesions which regulate tissue
generation, maintenance, and repair [61, 62]. Engler et al.
[63] demonstrated that variations in extracellular matrix
(ECM) alone are capable of aﬀecting hESC diﬀerentiation,
without any changes in serum conditions or soluble factors.
The cell niche is inherently three dimensional (3D) and its
biochemistry and topology strongly aﬀect the diﬀerentiation
and maturation process [64]. The main limitation of existent
two-dimensional (2D) cellular assays is that they do not
mimic the response of cells in the 3D milieu of tissues in vivo
[65, 66]. The use of 3D modelling systems may provide an
insight into cellular interactions and physiology that could be
translated to 2D models in vitro allowing the development
of a scalable high fidelity resources for drug testing or BAL
construction.
8. Tissue Architecture and the Role of
Extracellular Matrix
The ECM is well defined as the dynamic modulator of
various cellular processes including homeostasis, diﬀeren-
tiation, and repair [67]. Extracellular matrices are primar-
ily composed of four molecular groups: collagen, elastin,
structural glycoproteins, and proteoglycan. The complex
ECMs secreted by mammalian cells form intricate scaﬀolds
on which cells congregate and form 3D matrices. This
unique compositional and structural combination facilitates
biophysical and biochemical functions such as the transport
of soluble signalling molecules, nutrients, and metabolic
wastes, and provides mechanical integrity by absorbing
compressive and tensile stresses [68]. It is organized and
sensed by cells through integrins, which are membrane
spanning heterodimers modulating communication between
the ECM and the cell. The hepatic ECM has been studied
extensively due to its importance in hepatic homeostasis
and its prominent role in cirrhosis [69]. Hepatocytes exhibit
a striking polarity that is expressed at multiple levels, in
overall cell shape, distribution of the cytoskeleton and
organelles, and in the division of the plasma membrane into
three functionally and compositionally distinct domains:
basolateral, canalicular, and lateral. At the basal surface the
transport of small molecules across membranes and the
exchange of metabolites with blood take place, whereas the
secretion of bile acids and detoxification products occurs
on the apical domain [70]. The ability to modulate hepa-
tocyte polarity and multicellular organization is important
in developing in vitro systems designed to perform liver
functions. Extracellular matrix isolated from liver tissue has
been shown to maintain the phenotype of hepatocytes in
culture [71]. It has also been shown that optimisation of the
physical and chemical properties of ECM is important for
the maintenance of hepatocyte function in vitro [72], and
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this is essential for developing a BAL. Chang and Hughes-
Fulford [73] demonstrated that 3D culture of the hepatocyte
cell line, HepG2, in rotating wall vessel bioreactors led
to the formation of spheroids with enhanced cytochrome
P450 activity and albumin production. However, it should
be noted that transfer of the spheroids to tissue culture
dishes led to loss of function and disintegration. In another
study, albumin secretion activity in fetal liver cells was
shown to be one order of magnitude higher in cells
cultured on 3D porous polymer scaﬀolds than in those
grown in monolayers [74]. The limitations of existing 2D
tissue culture techniques have necessitated the creation of
3D microenvironments incorporating materials, implants,
and biophysical stimuli optimised for modulation of cell
functions [75].
9. Biomaterial Scaffolds: 3D Modelling
Scaﬀolds provide an architectural context in which cell-
matrix, cell-cell, and growth factor interactions combine to
create regenerative niches [76]. Biomaterial-based scaﬀolds
could provide a 3D environment for cells, both in culture
and inside the body. Such 3D systems have been shown to
enhance osteogenesis [77], hematopoiesis [78], and neural
diﬀerentiation [79, 80], and provide greater support for
hepatocyte proliferation and functionality than routine 2D
tissue culture [81, 82]. Recent research has focused on the
development of biomaterials designed to mimic the unique
characteristics of natural ECM. Ideal biomaterials should be
strong enough to bear the physiological load, be resistant
to undesired degradation or corrosion, noncarcinogenic,
nonimmunogenic, antileukotactic, and nonmutagenic. Bio-
compatibility is another important feature of biomaterials
and this depends on their material composition, surface
wettability, roughness, charge, size, and shape. The nature
of the biomaterial surface including its hydrophobicity and
hydrophilicity determines how proteins interact with the
surface upon adsorption [83]. The biomaterials in use for
tissue engineering can be broadly classified as biodegradable
and nonbiodegradable. The nonbiodegradable biomaterials
consist of metals, ceramics, and composites, which have
been used as integral components in bone and dental
replacements [84, 85]. The biodegradable biomaterials, both
natural and synthetic, closely resemble the consistency of
native tissue and make attractive scaﬀold materials for soft
tissue engineering. Polymers, both natural and synthetic, are
of special interest for liver engineering. They are organic
in nature and the most diverse of the biomaterials, varying
mechanically and physically, and possessing diﬀerent chem-
ical reactivities and degradation properties. Polymers oﬀer
greater flexibility in design, composition, and structure, and
can be tailored for specific needs.
The derivatives of natural ECM are used as biomaterials
for scaﬀolds in liver studies as it has been recognized
that in vivo cues such as ECM, cell signaling, and soluble
factors could hold the key to producing fully mature and
functional hepatocytes. Collagen is one such natural ECM
component found in bone, skin, ligaments, and connective
tissues. It provides a substrate for cellular recognition, cell
attachment, proliferation, and diﬀerentiation. Imamura et al.
[50] showed that hESCs cultured as EBs in a polypropylene
conical tube inserted into a collagen scaﬀold 3D culture
system supplemented with exogenous growth factors and
hormones were able to produce HE displaying liver gene
expression and albumin production. Similar success with
3D collagen culture systems was published by Baharvand
et al. [49]. Hyaluronic acid is another ECM component
found in embryonic and fetal tissues. It is involved in cell
expansion and proliferation and plays a prime role in cell
behaviour and cell signalling in vivo. Human hepatoblasts
and hepatic stem cells express hyaluronan receptors (CD44).
Hyaluronans are glycosaminoglycans and form highly reac-
tive biomaterials. Turner et al. [86] demonstrated the
formation of cell aggregates by hepatoblasts and hepatic stem
cells in hyaluronan hydrogels, which maintained viability
and phenotype for 4 weeks. However, the major drawbacks
of natural ECM components are their variable chemical
and physical properties and the ethical and safety issues
associated with their derivation. Therefore, plant, animal,
and insect components have been explored to develop
natural biomaterials such as silk, chitosan, alginate, and
matrigel. Silk fibroin is derived from silk worm cocoons and
has FDA approval for use in surgery and drug delivery. The
porous silk scaﬀolds are developed using gas foaming or
salt leaching techniques. Silk fibroin microfluid devices have
been shown to support proliferation and the development
of liver specific functions in HepG2 cells [87]. Chitosan
is a natural biopolymer consisting of glucosamine and
N-acetylglucosamine obtained by deacetylation of chitin.
Chitosan albumin matrix has been demonstrated to support
fetal porcine attachment for creating liver tissue organoids
[88]. Natural hydrogels such as matrigel and alginate have
been extensively used by several groups for 3D culture of
hepatocytes due to their biocompatibility, mild gelling con-
ditions, and improved cell entrapment properties. Matrigel
is composed of solubilized basement membrane proteins
extracted from mouse chondrosarcomas and consists of
laminin, collagen IV, and heparin sulphate proteoglycan
[84]. Hepatocytes cultured on matrigel have been shown to
cluster intomulticellular spheroids, but appear less polygonal
than hepatocytes in vivo [89, 90]. Although matrigel is an
excellent biomaterial because of its abundance of natural
biological molecules, its heterogeneous nature and unidenti-
fied molecular components reduce a degree of experimental
control. Additionally, its xeno origin and derivation from
chondrosarcoma limit its potential for cell therapies and
tissue engineering as per good manufacturing practice
(GMP) standards. Alginate is extracted from seaweed and
thus is readily available. It is composed of 2 monomers
(a-L guluronic acid and b-D mannuronic acid) and is an
attractive biomaterial because of its gelation property which
can occur through the addition of ionic cross linkers or
divalent cations such as Ca2+, Ba2+, and Sr2+ [91]. Alginate
has been used as a delivery system for drugs, an extracellular
material for basic biological studies, and as a scaﬀold for
tissue engineering [92]. Human EBs cultured in alginate
micro beads supplemented with exogenous growth factors
6 Journal of Biomedicine and Biotechnology
have been shown to diﬀerentiate into HE expressing alpha-
fetoprotein (AFP), albumin, CYP7A1, and cytokeratin 18
[93]. Cheng et al. showed that alginate gel encapsulation also
supports the growth and diﬀerentiation of hepatic progenitor
cells derived from human fetal livers [81]. Hepatocyte func-
tions such as ammonia detoxification, albumin secretion,
P450 expression, and the development of bile ducts were
also reported in this study. In another study, cultivation of
the C3A human hepatocyte cell line within alginate scaﬀolds
led to the formation of spheroids with improved drug
metabolism and phase II activity compared to 2D monolayer
cultures [82].
The use of natural polymers in 3D systems mimics in
vivo histoarchitecture and provides easy manipulation of
cells and tissues as well as promoting cell-matrix interactions.
These provide a microenvironment conducive to normal
progenitor cell kinetics and enhance cell diﬀerentiation.
The major disadvantages of using natural materials are the
limited control over physiochemical properties that they
oﬀer, as well as immunogenicity, degradability, lack of
reproducibility, and inconsistency in mechanical properties.
10. Synthetic Polymers
Synthetic biopolymers oﬀer an advantage over natural
materials as they can be tailored to possess a wide range of
properties, are GMP scalable, and can be made biocompati-
ble. Biodegradable polymer scaﬀolds provide frameworks for
tissue regeneration and cell transplantation and can be made
to degrade over time [94]. At present, the most common
biodegradable polymers in use or being studied include
polylactic acid (PLA), poly-L-lactic acid (PLLA), polyglycolic
acid (PGA), polyanhydrides, polyfumarates (PF), poly-
orthoesters, polycaprolactones (PCL), and polycarbonates
[95, 96].
Poly (α-hydroxy acids) consist of PGA and PLLA
homopolymers and their copolymers (PLGA), as well as
polylactic acid stereo copolymers produced using L-, D-, or
DL-lactides and racemic polymer copolymer PLDLA [97].
They are used in surgical sutures and implant devices [98]
and hence have been used by several research groups as
the material of choice for liver tissue engineering. Huang
et al. showed that PLLA polymer-based 3D culture with
appropriate biofactors promoted the functional maturation
of fetal porcine hepatocytes [99]. Jiang et al. [100] had similar
success, using a PLLA scaﬀold to culture mouse fetal liver
cells which produced albumin at levels comparable to adult
mouse hepatocytes. In vitro growth and maturation of rat
fetal liver cells on PLLA macroporous scaﬀolds has also
been reported. These cells maintained a high level of hepatic
function including albumin secretion and cytochrome P450
activity for 2 weeks, whilst monolayer function decreased
after 7 days in culture [101]. Furthermore, Cho et al. [102]
reported eﬃcient infection of hepatitis C virus and obtained
progeny of infective virus in the supernatant of 3D PEG
hydrogel encapsulated cells.
The limitations of poly (α hydroxy acids) include bulk
degradation, surface erosion, and hydrophobicity [103].
Degradation occurs by hydrolysis, accounting for the accu-
mulation of acid by-products which can lead to inflamma-
tory responses in vivo, specifically in areas of poor vascu-
larisation. These drawbacks could be reduced by scaﬀold
chemistry patterning using protein stamping, photochemical
modification, and the incorporation of specific bioactive
domains onto the scaﬀold surface for cell adhesion, migra-
tion, tissue ingrowth, and repair [104, 105].
Another group of synthetic polymers attracting attention
for hepatocyte 3D culture is polyurethanes. These are one of
the most broadly used polymers in implantable biomedical
devices such as artificial hearts, cardiac pacemakers and
structural tissue replacements [106]. Ijima et al. demon-
strated the formation of spherical multicellular aggregates of
adult rat hepatocytes in pores of polyurethane foam (PUF)
[107, 108]. The culture of porcine hepatocyte spheroids using
PUF has also been reported and translated to the clinic as a
hybrid artificial liver device [109]. More recently Matsumoto
et al. [110] demonstrated that mouse embryonic stem cells
formed spheroids on PUF foam, and that the addition
of specific growth factors initiated hepatic diﬀerentiation
and expression of HE markers such as AFP, albumin, and
tryptophan 2, 3-dioxygenase.
11. Design: Tailor Made Polymers for
Tissue Engineering
The advantage of using synthetic polymers is the wide
choice they oﬀer in design parameters including porosity,
pore connectivity, pore geometry, pore size distribution, and
surface topography. Such polymers can be designed to aid
eﬃcient diﬀusion of nutrients, metabolic wastes and soluble
molecules, and the facilitation of mass transport within 3D
matrices to control the eﬃciency of cell seeding [111]. They
can be tailored to achieve appropriate designs for specific
cell groups using diﬀerent approaches such as spin casting,
leaching, emulsion freeze drying, rapid prototyping, and
stereolithography [112].
It is increasingly being recognised that cells respond
to the physical characteristics of the substrate on which
they are grown [113]; therefore it is important to tune
features such as void and interconnect size, surface area and
mechanical properties for constructing biomaterial scaﬀolds.
The two morphological designs that have become more
popular among tissue engineers are fibrous matrices and
sponge-like matrices. Fibrous matrices have a high surface
area-to-volume ratio and a structure similar to the 3D fibre
network of collagen and elastin found in natural ECM. The
major disadvantage of fibrous structures is the presence of
small pores among the fibres which considerably hamper cell
migration. Sponge-like matrices have an advantage in their
design and structure with porosity and interconnectivity that
can be regulated. The HepG2 cell line cultured on sponge-
like polystyrene scaﬀolds has been shown to retain higher
levels of cell viability, cellular morphology, and hepatocyte
functionality compared to their counterparts cultured on
standard 2D plastic [114].
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Figure 2: Schematic diagram of 3D culture of hepatocytes on a polymer scaﬀold, and the potential applications of this technology.
Analysing the behaviour of cells on scaﬀolds is important
to ensure cell viability and function in tissue engineered
constructs [115]. However, the optimal distribution and
migration of seeded cells throughout the scaﬀold remains
an issue. The most common cell seeding techniques are
static seeding and dynamic seeding. Static seeding consists of
surface seeding and direct injection whereas dynamic seeding
involves the movement of cell solution through and around
the scaﬀold to achieve a more homogeneous distribution
[116]. Another popular technique is cell entrapment, which
has been extensively used in constructing 3D in vitro model
systems. Cell entrapment techniques are based on the self-
assembly of materials around cells, rather than the shaping
of a bulk material to specific architecture [117].
In vivo cellular interaction with ECM proteins is very
complex as these proteins present cells with multiple cell
binding and growth factor binding domains. To simulate
in vivo cellular interactions in vitro, the biomaterials can
be coated with specific amino acid subunits to attain
more defined conditions. The peptide sequence RGDS (arg-
gly-asp-ser) from vitronectin and fibronectin has been
recognized as a minimal sequence required for integrin
mediated cell adhesion [118]. Another such defined sequence
is IKVAV (ile-lys-val-ala-val) found in laminin [119]. Human
mesenchymal stem cells have been shown to change from
a fibroblast shape in a 2D culture system to a compact
shape on an RGD (arg-gly-asp) alginate culture system [120].
Furthermore, Hybrid RGD/galactose substratum has also
been shown to support hepatocyte functions [121].
Novel biomaterials are being designed to be able to
respond to biological environmental stimulation. Such
“smart materials” respond to specific cellular signals
and include hydrogels containing matrix metalloproteinase
degradable sites [122]. These allow native cells to control gel
remodelling such that cells replace the synthetic gel material
with tissue upon in vivo transplantation. These materials
could be made biocompatible and thereby avoid nonspe-
cific protein adsorption. Therefore, eﬀorts are focused on
developing 3D matrices containing self-assembling peptides
that could direct cellular diﬀerentiation to a specific lineage
[123]. Semino et al. [124] used self-assembling peptide
scaﬀolds to culture the rat hepatocyte progenitor cell line,
lig8. The resulting cell population derived in a 3D manner
showed expression of definitive endoderm markers such
as HNF3β, cytokeratin 8, and AFP. The expression of
mature hepatocyte markers however was not evident, despite
observation of other mature hepatocyte properties. Magnetic
nanoparticles and quantum dots have also been suggested
for stem cell labelling and in vivo tracking, and such
engineered nanometer-scale scaﬀolds could be used for stem
cell diﬀerentiation and transplantation [125].
The major limitation of tissue engineering methodolo-
gies is poor simulation of the complex architecture and
abundant vasculature of the liver. In vivo, cells at a distance
of more than 0.1mm from vascularity cannot survive and
cells within bioengineered tissue have similarly stringent
requirements, as diﬀusion within scaﬀolds is limited to a few
hundred micrometers [126]. Poyck et al. [127] have shown
in an AMC bioartificial liver model that long-term culture
of primary porcine hepatocytes is improved by increased
anaerobic glycolysis, which leads to better liver specific
function and metabolic stability. For this reason, in high
density liver cultures adequate delivery of oxygen to cells is
crucial. Synthetic oxygen carriers such as perflurocarbons
and cross-linked hemoglobin have been added onto scaﬀolds
to facilitate oxygenation [128]. The latest approach has
been the use of oxygen generating biomaterials, and it was
reported that PLGA scaﬀolds containing calcium peroxide-
based particles maintained elevated levels of oxygen and
extended cell viability under hypoxic conditions [129].
Microfabrication and computational fluid dynamics have
also been used to generate scaﬀold designs suitable for
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microvasculature and organ specific constructs [130–132].
Carraro et al. [133] demonstrated a microfluidics-based
bilayer device with discrete parenchymal chambers designed
using computational modelling. This device was able to
sustain human hepatoma cells, and primary rat hepatocytes.
By solving the problem of supplying cells grown in 3D tissue
culture with oxygen, it will be possible to sustain the culture
of hepatocytes in vitro for extended periods, facilitating cell
studies and eventually leading to the improved functionality
of BALs (Figure 2).
12. Conclusion
The future challenge in liver research is the development
of functional, reliable, xenofree HE that will bypass the
issues associated with PHHs. The derivation of HE from
hESCs could provide an unlimited source of cells for
BAL construction. The three-dimensional culture of these
cells with appropriate extracellular matrix and polymer-
based biomaterials could provide an alternative to porcine
hepatocytes leading to the generation of a humanised BAL
device. More recently the generation of induced pluripotent
stems cells (iPSCs), by transfection of key pluripotency genes
into somatic cells, has led to a new era in regenerative
medicine. These cells are free from the ethical complications
associated with hESCs and can be tailor-made for patients.
HE derived from iPSCs and its incorporation into a BAL
device may therefore play an important role in the treatment
of human liver disease and the prediction of drug toxicity.
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